Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment options in multiple sclerosis.

Adrienne Boissy1, Robert J Fox

  • 1Robert J. Fox, MD Mellen Center for Multiple Sclerosis, 9500 Euclid Avenue, U-10, Cleveland, OH 44122, USA. foxr@ccf.org.

Current Treatment Options in Neurology
|April 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis.

Drugs·2026
Same author

Use of semaglutide and tirzepatide among people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Tolebrutinib Phase 2b Long-Term Extension Study: Two-Year Safety, MRI, and Clinical Efficacy Outcomes in Patients With Relapsing Multiple Sclerosis Patients.

Neurology open access·2026
Same author

Evaluation of cortical pathology in primary-progressive multiple sclerosis: a post hoc analysis of the SPRINT-MS trial.

BMJ neurology open·2026
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Early treatment for multiple sclerosis (MS) is crucial for managing disability. Advances in understanding MS pathogenesis are driving new, targeted therapies, with several promising treatments in late-stage trials.

Area of Science:

  • Neuroimmunology
  • Neurology
  • Clinical Therapeutics

Background:

  • Multiple sclerosis (MS) pathogenesis involves complex immune responses and neuroinflammation.
  • Axonal damage contributes significantly to progressive disability in MS.
  • Understanding lesion development is key to targeted therapeutic strategies.

Purpose of the Study:

  • To review current understanding of MS pathogenesis and lesion development.
  • To discuss the role of early and aggressive treatment in MS management.
  • To highlight emerging and established therapeutic options for MS.

Main Methods:

  • Review of current literature on MS pathogenesis and treatment.
  • Analysis of clinical trial data for disease-modifying therapies.

Related Experiment Videos

  • Discussion of therapeutic strategies for acute exacerbations and chronic progression.

    • Main Results:

    • Early treatment with disease-modifying therapies is recommended for patients with a first demyelinating episode and MS-consistent MRI lesions.
    • Intravenous steroids are standard for acute MS relapses.
    • Natalizumab and mitoxantrone effectively reduce relapses and MRI lesions in relapsing MS.

    Conclusions:

    • Targeted therapies for MS are advancing due to improved understanding of disease mechanisms.
    • Early intervention is critical to mitigate accumulating disability.
    • Numerous novel oral and infusion therapies are nearing availability, expanding future treatment options.